Clinical Trial Update: A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LJPC-501 for catecholamine-resistant hypotension completed, with results posted in January 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catecholamine-resistant Hypotension
• Distributive Shock
• Sepsis

Drugs mentioned

• LJPC-501

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Catecholamine-resistant Hypotension (CRH), Distributive Shock | Phase 3 | Status: COMPLETED | Results posted: 2018-01-17